Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/Cyclin D1 gene

doi:10.1016/0046-8177(95)90090-X

Human Pathology

Volume 26, Issue 9, September 1995, Pages 999-1004

https://doi.org/10.1016/0046-8177(95)90090-X Get rights and content

Abstract

Centrocytic/mantle cell lymphoma (CC/MCL) is a morphologically defined B-cell non-Hodgkin's lymphoma characterized by a distinctive immunophenotype, BCL1/cyclin Dl (PRAD1) gene rearrangements, and, most recently, by overexpression of cyclin Dl. Even using multiple breakpoint probes for BCL1 (MTC, p94PS) and cyclin Dl, however, only approximately 70% of CC/MCL have a rearrangement consistent with a t(11;14) (q13;q32). To determine whether the type of molecular translocation affects the degree of cyclin Dl expression and to evaluate lymphomas diagnosed as CC/ MCL but lacking molecular evidence of a BCL1 or cyclin D1 translocation, 16 CC/MCL and four cases of small lymphocytic lymphoma/ B-CL1 (SLL/B-CLL) were stained using an anti-cyclin Dl antibody. All cases with a cyclin Dl translocation detected by Southern blotting techniques as well as four of the five CC/MCL without a documentable translocation showed nuclear cyclin Dl protein expression. There was no apparent correlation between staining intensity and the precise site or presence of a detectable translocation. Cases with a mantle zone growth pattern showed infiltration of the cyclin D1 positive cells into reactive follicular centers. None of the four SLL/B-CLL showed cyclin Dl expression. These findings show overexpression of the cyclin Dl protein in virtually all CC/MCL independent of the type or presence of a documentable BCL1 or cyclin Dl molecular rearrangement. The mechanism for cyclin D1 overexpression in the cases without a documentable rearrangement and the relationship of cyclin Dl overexpression to the pathogenesis of mantle cell neoplasia remain uncertain.

References (37)

E Zucca et al.
ME Williams et al.
Genotypic characterization of centrocytic lymphoma: Frequent rearrangement of the chromosome 11 bcl-1 locus
Blood
(1990)
ME Williams et al.
Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: Analysis with multiple breakpoint probes
Blood
(1991)
ME Williams et al.
Cyclin Dl overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement
Ann Oncol
(1994)
LJ Medeiros et al.
Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation
Blood
(1990)
R Rimokh et al.
Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas
Blood
(1994)
RJ Molot et al.
Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas
Blood
(1994)
SH Swerdlow et al.
Growth fraction in centrocytic and follicular center cell lymphomas: Assessment in paraffin sections with a proliferating cell nuclear antigen antibody and morphometric correlates
Hum Pathol
(1993)
R Rimokh et al.
Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias
Blood
(1993)
F Bosch et al.
PRAD-1/Cyclin Dl gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma
Blood
(1994)

D Jadayel et al.

Splenic lymphoma with villous lymphocytes: Analysis of bcl-1 rearrangements and expression of the cyclin Dl gene

Blood

(1994)

K Lennert et al.

Cytological and functional criteria for the classification of malignant lymphomata

Br J Cancer

(1975)

R Gerard-Marchant et al.

Classification of non-Hodgkin's lymphomas

Lancet

(1974)

G Tolksdorf et al.

Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes)

Br J Cancer

(1980)

SH Swerdlow et al.

Centrocytic lymphoma: A distinct clinicopathologic and immunologic entity

NL Harris et al.

Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies: Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities

Am J Pathol

(1984)

PM Banks et al.

Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data

Am J Surg Pathol

(1992)

SH Swerdlow et al.

Centrocytic lymphoma: A distinct clinicopathologic, immunophenotypic, and genotypic entity

Pathol Annu

(1993)

Cited by (101)

Mantle cell lymphoma continues to surprise, and inform!
2021, Blood
Treatment of mantle cell lymphoma in older adults
2018, Journal of Geriatric Oncology
Citation Excerpt :
On pathologic evaluation morphology varies from small to large atypical lymphocytes. Diagnosis requires a combination of flow cytometry (CD20 +, CD5 +, CD10 −, CD23 −), fluorescence in-situ hybridization for t(11;14), and immunohistochemical staining for cyclin D1 overexpression [6,7]. The clinical behavior of MCL is typically that of an aggressive lymphoma similar to the more common diffuse large B cell lymphoma (DLBCL), with development of symptoms over weeks to several months and a rapid response after initiation of treatment.
Mantle cell lymphoma (MCL) predominantly affects older adults, with a median age at diagnosis of 70 years. A frequently aggressive yet incurable lymphoma, the goal of therapy for MCL is to turn a potentially life-threatening illness into a chronic disease with prolonged periods of remission. Large randomized trial data supports the standard treatment in younger patients of cytarabine-based induction followed by autologous stem cell transplant. Most patients will not be eligible for this intensive approach based on older age, comorbidities, and functional status, making the geriatric assessment an essential step in choosing the appropriate strategy. For these older patients, an increasing number of chemotherapy and non-chemotherapy based therapies are available that allow oncologists to better tailor treatment to the fitness of the patient. We will review treatment options for older patients with MCL in the first line and relapsed/refractory settings, highlighting the available evidence for providing longer progression-free intervals while also minimizing the adverse effects of unduly aggressive treatment.
Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma
2013, Experimental Hematology
Molecular diagnosis of mantle cell lymphoma (MCL) can be difficult because the t(11;14)/IGH@-CCND1 is extremely heterogeneous at the DNA level. Aiming to establish a reliable molecular tool that could be easily implemented in routine diagnostics, we developed a new real-time polymerase chain reaction (PCR) assay for CCND1 expression measurement and evaluated 451 cases: 142 MCL, 76 chronic lymphocytic leukemia, 20 hairy cell leukemia, 13 hairy cell leukemia-variant, 20 splenic marginal zone lymphoma, 91 other mature B-cell neoplasms, 29 other hematologic neoplasms, and 60 healthy individuals. Sensitivity of the real-time PCR assay was up to 10⁻⁴. In t(11;14)/IGH@-CCND1 positive lymphoma samples (n = 150), median %CCND1/ABL1 expression level was 178.2 (range: 1.5–4, 152.0). Normalized by t(11;14)/IGH@-CCND1 positive cells as determined by fluorescence in situ hybridization IGH@-CCND1 positive samples showed a median %CCND1/ABL1 of 445.8 (range: 17.9–4,848.5). A normalized %CCND1/ABL1 expression of at least 17.0 was chosen as threshold for CCND1 positivity. For unnormalized samples, the positive detection rate of t(11;14)/IGH@-CCND1 by CCND1 expression was 87.3%. Healthy individuals had low %CCND1/ABL1 (median, 1.1; range, 0.0–7.8). The negative predictive value for exclusion of a t(11;14)/IGH@-CCND1 by CCND1 expression was 95.3% by the above threshold. %CCND1/ABL1 was higher in MCL than in the remaining B-cell lymphomas (mean ± SD, 392.9 ± 685.3 vs. 46.0 ± 305.0; p < 0.001). In 66 follow-up samples, CCND1 showed 2.5–3.5 log reduction after chemotherapy and increase at relapse. CCND1 expression could serve as adjunct to other techniques in diagnosis and follow-up of B-cell lymphomas.
Candidate genes contributing to the aggressive phenotype of mantle cell lymphoma
2011, Acta Histochemica
Citation Excerpt :
Pre-GC SLL lacks the genetic refinements observed in generating high-affinity antibodies during the GC reaction and can have a more aggressive clinical course than does post-GC SLL, which shows no genetic evidence of antibody gene alterations from passing through the GC (Klein and Dalla-Favera, 2008; Perez-Galan et al., 2010). Unlike MCL and many other classes of lymphoma, pre- or post-GC CLL and SLL are not characterized by a common oncogenic translocation (Guipaud et al., 2003; Swerdlow et al., 1995). Despite a poor response to conventional therapies, post-GC CLL/SLL is most often characterized by a prolonged indolent period with a median survival time between seven and ten years (Binet et al., 1981; Dighiero et al., 1981).
Mantle cell lymphoma and small lymphocytic lymphoma are lymphocyte cancers that have similar morphologies and a common age of onset. Mantle cell lymphoma is generally an aggressive B cell lymphoma with a short median survival time, whereas small lymphocytic lymphoma is typically an indolent B cell lymphoma with a prolonged median survival time. Using primary tumor samples in bi-directional suppression subtractive hybridization, we identified genes with differential expression in an aggressive mantle cell lymphoma versus an indolent small lymphocytic lymphoma. “Virtual” Northern blot analyses of multiple lymphoma samples confirmed that a set of genes was preferentially expressed in aggressive mantle cell lymphoma compared to indolent small lymphocytic lymphoma. These analyses identified mantle cell lymphoma-specific genes that may be involved in the aggressive behavior of mantle cell lymphoma and possibly other aggressive human lymphomas. Interestingly, most of these differentially expressed genes have not been identified using other techniques, highlighting the unique ability of suppression subtractive hybridization to identify potentially rare or low expression genes.
Immunohistology of Non-Hodgkin Lymphoma
2011, Diagnostic Immunohistochemistry
Immunohistology of Non-Hodgkin Lymphoma: Follicular Lymphoma versus Reactive Hyperplasia.
2010, Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, Expert Consult

View all citing articles on Scopus

^☆: Supported in part by American Cancer Society Research Grant CB69529 and NCI Cancer Center Support Grant P30-44579 (MEW).

^☆☆: This work was also supported in part by the Pathology Education and Research Foundation, Pittsburgh, PA.

View full text

Original contributionExpression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/Cyclin D1 gene☆,☆☆

Abstract

Blood

Blood

Ann Oncol

Blood

Blood

Blood

Hum Pathol

Blood

Blood

Blood

Cytological and functional criteria for the classification of malignant lymphomata

Br J Cancer

Classification of non-Hodgkin's lymphomas

Lancet

Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes)

Br J Cancer

Centrocytic lymphoma: A distinct clinicopathologic and immunologic entity

Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies: Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities

Am J Pathol

Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data

Am J Surg Pathol

Centrocytic lymphoma: A distinct clinicopathologic, immunophenotypic, and genotypic entity

Pathol Annu

Original contribution
Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/Cyclin D1 gene☆,☆☆